Selective sentinel lymphadenectomy for malignant melanoma

Area of Science:

• Oncology
• Surgical Pathology
• Nuclear Medicine

Background:

• Melanoma staging is critical for treatment planning.
• Sentinel lymph node biopsy (SLNB) is a key staging procedure.
• Accurate SLNB requires multidisciplinary expertise.

Purpose of the Study:

• To establish selective sentinel lymphadenectomy (SSL) as a standard staging approach for invasive melanoma.
• To outline the essential techniques for performing SSL.
• To define the role of SLN evaluation in melanoma management.

Main Methods:

• Preoperative lymphoscintigraphy for lymphatic mapping.
• Intraoperative identification of sentinel lymph nodes (SLNs) using radioactive tracers and/or dyes.
• Pathologic evaluation of SLNs, including size and radioactivity criteria.
• Complete lymph node dissection if SLN is positive.

Main Results:

• SSL is recommended for primary invasive melanoma ≥ 1 mm.
• SLNs are defined by radioactivity, dye uptake, or physical characteristics.
• Frozen section analysis of SLNs is not advised.
• Delayed SSL is an option for extremity melanomas.
• Complete lymph node dissection is indicated for positive SLNs.

Conclusions:

• Selective sentinel lymphadenectomy (SSL) is the standard of care for staging invasive melanoma.
• Mastery of lymphoscintigraphy, lymphatic mapping, and SLN pathology is essential.
• Complete lymph node dissection should be reserved for positive SLNs.
• Further clinical outcome studies are needed to refine the role of SSL.